The preservation of skeletal muscle mass is a key element in maintaining insulin sensitivity; hence, preserving skeletal muscle mass and performance while decreasing VAT should be considered one therapeutic goal of T2D and MAFLD. The gene discussed is INS; the disease is type 2 diabetes mellitus.